Bisloc 5mg Tablet

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

BISOPROLOL FUMARATE

Boleh didapati daripada:

MEDISPEC (M) SDN.BHD

INN (Nama Antarabangsa):

BISOPROLOL FUMARATE

Unit dalam pakej:

100 Tablets

Dikeluarkan oleh:

UNISON LABORATORIES CO.LTD

Ciri produk

D:\WorkPD_2021/BISLOC 2.5-5

Orapan_Job Print: 18-06-21 Scale 100%



Product
Code No.
Dimension
Packaging Type
Thickness
Designed by:
(PDM, PDC-M, PDC-A, PDO-M, PDO-A)
Checked by:
(PDM/ASPD)
Approved by:
PLC:
(Date)
LRA:
(Date)
Approved by:
(MD
(Only Pattern and Colors)
)
IRA:
(Date)
QCC-PM:
(Date)
CUSTOMER/SALES DEPT.:
(Date)



FRONT
29.5 cm.
16.5 cm.
BETA-ADRENERGIC BLOCKING AGENT
Each film coated tablet contains:
BISOPROLOL FUMARATE 2.5 MG
BISOPROLOL FUMARATE 5 MG
MECHANISM OF ACTION:
_PHARMACOLOGY_
Bisoprolol fumarate, a cardioselective inhibitor of
beta(1)-adrenoceptor, has no significant intrinsic sympathomimetic
activity or membrane
stabilizing activity in its therapeutic dosage. It also exhibits
beta(2)-adrenoceptors inhibition and negative chronotropic effect.
_PHARMACOKINETICS_
Absorption
Bisoprolol is almost completely absorbed from the gastrointestinal
tract and undergoes only minimal first-pass metabolism resulting in an
oral
bioavailability of about 90%. Peak plasma concentrations occur 2 to 4
hours after oral doses.
Distribution
Bisoprolol is about 30% bound to plasma proteins. Bisoprolol is
moderately lipid-soluble.
Metabolism
It is metabolized in the liver.
Elimination
It has a plasma elimination half-life of 10 to 12 hours.
It is excreted in urine, about 50% as unchanged drug and 50% as
metabolites.
INDICATION:
For 2.5 mg:
• Treatment of stable chronic heart failure with reduced systolic
left ventricular function in addition to ACE inhibitors, and
diuretics, and
optionally cardiac glycosides
For 5 mg:
• Treatment of high blood pressure (hypertension)
• Treatment of coronary heart disease (angina pectoris)
• Treatment of stable chronic heart failure with reduced systolic
left v